The University of Chicago Header Logo

Connection

James Millis to Immunosuppressive Agents

This is a "connection" page, showing publications James Millis has written about Immunosuppressive Agents.
Connection Strength

1.571
  1. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14(2):356-66.
    View in: PubMed
    Score: 0.331
  2. Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation. Cell Transplant. 2021 Jan-Dec; 30:9636897211001774.
    View in: PubMed
    Score: 0.134
  3. Treatment of liver allograft rejection. Liver Transpl Surg. 1999 Jul; 5(4 Suppl 1):S98-S106.
    View in: PubMed
    Score: 0.121
  4. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients. Transplant Proc. 1998 Jun; 30(4):1435-6.
    View in: PubMed
    Score: 0.112
  5. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. Transplant Proc. 1997 Feb-Mar; 29(1-2):1549.
    View in: PubMed
    Score: 0.102
  6. Potential role of Neoral in pediatric liver transplantation. Transplant Proc. 1996 Aug; 28(4):2267-9.
    View in: PubMed
    Score: 0.099
  7. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplant Proc. 1996 Apr; 28(2):1014.
    View in: PubMed
    Score: 0.096
  8. Coating human pancreatic islets with CD4(+)CD25(high)CD127(-) regulatory T cells as a novel approach for the local immunoprotection. Ann Surg. 2011 Sep; 254(3):512-8; discussion 518-9.
    View in: PubMed
    Score: 0.070
  9. Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transpl. 2010 Aug; 16(8):930-42.
    View in: PubMed
    Score: 0.065
  10. Modern immunosuppression. Clin Liver Dis. 2000 Aug; 4(3):619-55, ix.
    View in: PubMed
    Score: 0.033
  11. Liver transplantation at the University of Chicago. Clin Transpl. 1999; 231-8.
    View in: PubMed
    Score: 0.029
  12. Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
    View in: PubMed
    Score: 0.028
  13. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. Transplant Proc. 1998 Jun; 30(4):1249-50.
    View in: PubMed
    Score: 0.028
  14. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. Transplant Proc. 1998 Jun; 30(4):1378-9.
    View in: PubMed
    Score: 0.028
  15. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Jun; 30(4):1538-40.
    View in: PubMed
    Score: 0.028
  16. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Mar; 30(2):507-8.
    View in: PubMed
    Score: 0.027
  17. Reversal of accelerated renal allograft rejection with FK 506. Clin Transplant. 1997 Aug; 11(4):251-4.
    View in: PubMed
    Score: 0.026
  18. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Transplant Proc. 1997 Feb-Mar; 29(1-2):307.
    View in: PubMed
    Score: 0.026
  19. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation. 1996 Oct 15; 62(7):906-10.
    View in: PubMed
    Score: 0.025
  20. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. Clin Transplant. 1996 Aug; 10(4):323-32.
    View in: PubMed
    Score: 0.025
  21. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Clin Transplant. 1996 Aug; 10(4):389-95.
    View in: PubMed
    Score: 0.025
  22. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996 May 15; 61(9):1365-9.
    View in: PubMed
    Score: 0.024
  23. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplant Proc. 1996 Apr; 28(2):998-9.
    View in: PubMed
    Score: 0.024
  24. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32.
    View in: PubMed
    Score: 0.018
  25. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010 Nov 18; 363(21):2004-14.
    View in: PubMed
    Score: 0.017
  26. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation. 2004 Apr 27; 77(8):1269-75.
    View in: PubMed
    Score: 0.011
  27. Liver transplantation in the first three months of life. Transplantation. 1998 Sep 15; 66(5):606-9.
    View in: PubMed
    Score: 0.007
  28. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation. 1998 Feb 15; 65(3):393-6.
    View in: PubMed
    Score: 0.007
  29. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation. 1996 Aug 15; 62(3):370-5.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.